BioMedNewsBreaks – Cardiff Oncology Inc. (NASDAQ: CRDF) Announces Pricing of Underwritten Public Offering

October 9, 2020 10:43:43

Cardiff Oncology (NASDAQ: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, recently announced the pricing of its previously announced underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $13.50 per share. Cardiff Oncology anticipates receipt of approximately $88 million in gross proceeds from the offering, which is expected to close on or about October 2, 2020, subject to the satisfaction of customary conditions. The company has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares at the public offering price, less underwriting discounts and commissions. Cardiff Oncology intends to use the net proceeds for clinical development of its product candidate, onvansertib, as well as for working capital and other general corporate purposes.

To view the full article, visit

About Cardiff Oncology Inc.

Cardiff Oncology (formerly Trovagene Inc.) is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. The company’s goal is to overcome resistance, improve response to treatment and increase overall survival. Cardiff Oncology is developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (“PLK1”) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment. Cardiff Oncology has three ongoing clinical programs that are demonstrating the safety and efficacy of onvansertib: a Phase 1b /2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer (“mCRC”); a Phase 2 study of onvansertib in combination with Zytiga(R) (abiraterone)/prednisone in metastatic castration-resistant prostate cancer (“mCRPC”); and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (“AML”). For more information, please visit

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork